Immunotherapy targeting the PD-1/PD-L1 pathway showed enhanced clinical benefits for PD-L1-positive cervical cancer patients, manifesting improved ORR, DCR, median PFS, and median OS periods (67). This evidence concerns the gene CD274 and cervical cancer.